Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

被引：0

作者：

Karvouni, Maria ^{[1
]}

Zhou, Heyue ^{[2
]}

Kathleen, Arnika ^{[1
]}

Ma, Qiangzhong ^{[2
]}

Baloch, Alamdar H. ^{[1
]}

Zhu, Tong ^{[2
]}

Zhang, Hong ^{[2
]}

Gilljam, Mari ^{[3
]}

Lundqvist, Andreas ^{[4
]}

Kaufmann, Gunnar F. ^{[2
]}

Alici, Evren ^{[1
]}

机构：

[1] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden

[2] Sorrento Therapeut Inc, San Diego, CA USA

[3] Karolinska Inst, Stockholm, Sweden

[4] Karolinska Inst, Dept Ocol Pathol, Stockholm, Sweden

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-127893

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1848

引用

页数：2

共 50 条

[21] A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells
Rossi, Ann Marie
Bunin, Anna
Iben, Lawrence
Welsch, Matthew
Berbasova, Tanya
Riillo, Caterina
Rossi, Marco
Ohuchi, Masaki
Alvarez, Enrique
Kawakami, Naoko
Nagasawa, Takayuki
Tassone, Pierfrancesco
Spiegel, David
Rastelli, Luca
BLOOD, 2019, 134
[22] Optimized affinity CD38 CAR-NK cells with CD38 KO show promising in-vivo activity in a multiple myeloma model
O'Dwyer, Michael
Shevlin, Enda
Brophy, Sarah
Hermanson, David
Hintz, Hallie
Otto, Neil
Ettestad, Brianna
Kirkham-McCarthy, Lucy
Koylijarvi, Marjut
Hardwicke, David
Reilly, Mary
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S45 - S46
[23] The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Shallis, Rory M.
Terry, Christopher M.
Lim, Seah H.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (06) : 697 - 703
[24] The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Rory M. Shallis
Christopher M. Terry
Seah H. Lim
Cancer Immunology, Immunotherapy, 2017, 66 : 697 - 703
[25] Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
Lejeune, Margaux
Duray, Elodie
Peipp, Matthias
Clemenceau, Beatrice
Baron, Frederic
Beguin, Yves
Caers, Jo
CANCERS, 2021, 13 (12)
[26] CD38 restrains the activity of extracellular cGAMP in a model of multiple myeloma
Cuollo, Lorenzo
Di Cristofano, Samuele
Sandomenico, Annamaria
Iaccarino, Emanuela
Oliver, Angela
Zingoni, Alessandra
Cippitelli, Marco
Fionda, Cinzia
Petillo, Sara
Kosta, Andrea
Tassinari, Valentina
Petrucci, Maria Teresa
Fazio, Francesca
Ruvo, Menotti
Santoni, Angela
Raimondo, Domenico
Soriani, Alessandra
ISCIENCE, 2024, 27 (05)
[27] Loss of CD38 expression in myelomatous pleural effusion in a patient with myeloma treated with daratumumab: Report of a case
Sasaki, Natsuki
Ishida, Kazuyuki
Yanagawa, Naoki
Nishiya, Masao
Yashima-Abo, Akiko
Kikuchi, Inako
Yamada, Noriyuki
Ambo, Junichi
Kiyohara, Kazuki
Osakabe, Mitsumasa
Uesugi, Noriyuki
Ito, Shigeki
Sugai, Tamotsu
DIAGNOSTIC CYTOPATHOLOGY, 2021, 49 (01) : 168 - 170
[28] Upregulation of CD38 Expression on Multiple Myeloma Cells By the HDAC Inhibitor Ricolinostat Augments the Efficacy of Daratumumab
Garcia-Guerrero, Estefania
Danhof, Sophia
Schreder, Martin
Perez-Simon, Jose A.
Einsele, Hermann
Hudecek, Michael
BLOOD, 2017, 130
[29] DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
Choudhry, Priya
Mariano, Margarette C.
Geng, Huimin
Martin, Thomas G., III
Wolf, Jeffrey L.
Wong, Sandy W.
Shah, Nina
Wiita, Arun P.
LEUKEMIA, 2020, 34 (03) : 938 - 941
[30] Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma
Cho, Nicholas
Ko, Sooah
Shokeen, Monica
MOLECULAR IMAGING AND BIOLOGY, 2021, 23 (02) : 186 - 195

← 1 2 3 4 5 →